Classification of amyloidosis by laser microdissection and mass spectrometry–based proteomic analysis in clinical biopsy specimens

The clinical management of amyloidosis is based on the treatment of the underlying etiology, and accurate identification of the protein causing the amyloidosis is of paramount importance. Current methods used for typing of amyloidosis such as immunohistochemistry have low specificity and sensitivity...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 114; no. 24; pp. 4957 - 4959
Main Authors Vrana, Julie A., Gamez, Jeffrey D., Madden, Benjamin J., Theis, Jason D., Bergen Robert, H., Dogan, Ahmet
Format Journal Article
LanguageEnglish
Published Washington, DC Elsevier Inc 03.12.2009
Americain Society of Hematology
Subjects
Amyloidosis
Amyloidosis - classification
Biological and medical sciences
Female
Hematologic and hematopoietic diseases
Humans
Lasers
Male
Medical sciences
Metabolic diseases
Microdissection - methods
Other metabolic disorders
Proteomics - methods
Sensitivity and Specificity
Tandem Mass Spectrometry - methods
Hematology
Microdissection
Exploration
Metabolic diseases
Enzymopathy
Protein
Anatomic pathology
Biopsy
Classification
Laser
Proteomics
Amyloidosis
Mass spectrometry
Online AccessGet full text

Cover

More Information
Summary:The clinical management of amyloidosis is based on the treatment of the underlying etiology, and accurate identification of the protein causing the amyloidosis is of paramount importance. Current methods used for typing of amyloidosis such as immunohistochemistry have low specificity and sensitivity. In this study, we report the development of a highly specific and sensitive novel test for the typing of amyloidosis in routine clinical biopsy specimens. Our approach combines specific sampling by laser microdissection (LMD) and analytical power of tandem mass spectrometry (MS)–based proteomic analysis. We studied 50 cases of amyloidosis that were well-characterized by gold standard clinicopathologic criteria (training set) and an independent validation set comprising 41 cases of cardiac amyloidosis. By use of LMD/MS, we identified the amyloid type with 100% specificity and sensitivity in the training set and with 98% in validation set. Use of the LMD/MS method will enhance our ability to type amyloidosis accurately in clinical biopsy specimens.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2009-07-230722